Raising the bar for using surrogate endpoints in drug regulation and health technology assessment
Authors:
Abstract
Surrogate endpoints provide no guarantee of clinical benefit, and Dalia Dawoud and colleagues argue they should be used only as a last resort in drug trialsKeywords
This publication has 55 references indexed in Scilit:
- The idolatry of the surrogateBMJ, 2011
- Reputation and Precedent in the Bevacizumab DecisionNew England Journal of Medicine, 2011
- Surrogate endpoints for EDSS worsening in multiple sclerosisNeurology, 2010
- Surrogate outcomes in health technology assessment: An international comparisonInternational Journal of Technology Assessment in Health Care, 2009
- Related Causal Frameworks for Surrogate OutcomesBiometrics, 2009
- Evaluation of Tumor Response, Disease Control, Progression-Free Survival, and Time to Progression As Potential Surrogate End Points in Metastatic Breast CancerJournal of Clinical Oncology, 2008
- Progression-Free Survival Is a Surrogate for Survival in Advanced Colorectal CancerJournal of Clinical Oncology, 2007
- Validation of Surrogate end Points in Multiple Randomized Clinical Trials with Failure Time end PointsJournal of the Royal Statistical Society Series C: Applied Statistics, 2001
- The validation of surrogate endpoints in meta-analyses of randomized experimentsBiostatistics, 2000
- CD4 cell count as a surrogate endpoint in HIV clinical trialsAIDS, 1998